IMA204 / Immatics - LARVOL DELTA

Immatics Announces Third Quarter 2022 Financial Results and Business Update (GlobeNewswire) - "ACTengine® IMA204 (COL6A3 exon 6):...The TCR-T candidate, IMA204 was able to eliminate tumor cells at physiological target levels in in vitro studies and in vivo mouse models. Due to Immatics focusing its clinical resources on the three IMA203 Phase 1b cohorts as well as accelerating the clinical development for the PRAME TCER® IMA402, the company has delayed the IND submission for an ACTengine® candidate directed against COL6A3 exon 6."

Preclinical • Oncology

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) - "IND submission for IMA203CD8 as part of the Phase 1b study expansion cohort is expected in the first half of 2022...TCER® IMA402...Production of GMP material for a Phase 1 clinical study is planned in 2022...R&D expenses were €21.2 million ($24.5 million1) for the three months ended September 30, 2021...The increase is mainly due to expanded clinical activities for the ACTengine® IMA200 series, as well as GMP manufacturing for the TCER® compound, IMA401."

Commercial • New P1 trial • Hematological Malignancies • Oncology • Solid Tumor

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME (GlobeNewswire) - "IND-enabling studies are close to completion. Submission of the IND application for IMA204 is now expected in 2022 to allow accelerated initiation of the multiple ACTengine® IMA203 Ph1b cohorts."

IND

Immatics Announces First Quarter 2021 Financial Results and Business Update (GlobeNewswire) - “ACTengine® IMA200 series...programs, IMA201, IMA202 and IMA203... trials continue to recruit according to plan with eight trial sites active in both Europe and the US. A data update is expected in H2 2021 with additional patients being treated, including initial data from patients treated at the target dose. The fourth program of the ACTengine® IMA200 series, IMA204…the Federal German regulatory authority, submission of a clinical trial application (CTA) remains on track for Q4 2021…The company’s first TCER® program, IMA401 remains on track for submission of a clinical trial application (CTA) by year end 2021.”

Enrollment status • European regulatory • Trial status • Oncology • Solid Tumor

Immatics Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment (GlobeNewswire) - "IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy numbers in tumor stroma across many solid cancers. Two affinity-enhanced TCR candidates designed using Immatics’ proprietary XCEPTOR™ platform demonstrates high specificity and potency; one of the candidates shows full functionality also in CD4+ T cells without requirement for a CD8 co-receptor. Submission of IND application to FDA for IMA204 remains on track for 2021…Immatics will discuss the IMA204 preclinical data at the Hanson Wade CAR-TCR Digital Week on September 14th."

IND • Preclinical • Oncology